They have already taken the weight-loss sector by storm - now the blockbuster drugs Ozempic and Mounjaro could do the same ...

Novo Nordisk said it's ending its collaboration due to concerns with Hims & Hers the company's sales and promotion of cheap ...

Novo Nordisk cut off Hims & Hers Health from selling lower-priced Wegovy on Monday morning, but its explanation for the ...

Novo Nordisk ended an agreement with Hims & Hers that had allowed the telehealth firm to offer the Wegovy weight-loss drug to its customers. U.S. equities advanced at midday as oil prices declined on ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

Hims & Hers stock plummeted around 30% in early trading Monday after Novo Nordisk announced it was ending a collaboration to ...

While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...

Novo Nordisk has announced it is ending its distribution collaboration with US telehealth firm Hims & Hers Health over the ...

Novo Nordisk's U.S.-listed shares fell more than 5% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

Hims & Hers stock has fallen nearly 30% on Monday after Novo Nordisk announced it is ending its collaboration with the telehealth company, saying they sell knock-off ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 29.2% in the morning session after Novo Nordisk, the maker ...